TearSolutions: Funding, Investors & Team (Sep 2026)
TearSolutions Inc. is a Delaware Corporation based in Charlottesville, VA. The company has successfully completed a well-powered 204 patient Phase II Proof of Concept clinical trial for the treatment of ocular surface disease in primary Sjögren’s Syndrome patients. Statistically significant improvement in both sign and symptom at two weeks was found. The trial compared vehicle and two doses of LacripepTM, a novel 19 AA peptide that is present in normal tears and deficient in all forms of dry eye. The peptide restores homeostasis to the ocular surface, in particular the barrier function of the corneal epithelium and normal function of sensory nerves at the corneal surface in preclinical animal models. Restoration of epithelial barrier function can be measured clinically as a decrease in corneal fluorescein staining while the improvement in sensory nerve function restores normal production of the components of tears: the aqueous via reinnervation of lacrimal glands, the lipid via reinnervation of meibomium glands and the mucin via reinnervation of goblet cells. Improvement in fluorescein staining and tear production (Schirmer tear test) are clinical ‘signs’ of ocular suface disease that have been used in the FDA approval of Xiidra and Restasis, respectively. Lacripep was discovered at the University of Virginia with NIH National Eye Institute funding as a naturally occurring fragment of the larger 119 AA protein, lacritin, in an unbiased screen for novel factors capable of addressing dry eye. Management team - CEO/President: Anil Asrani - Executive Chair: Robert Dempsey - CSO/Cofounder: Gordon W. Laurie PhD, FARVO - CFO: Colin M. Rolph - Chief Regulatory Officer: Michelle Carpenter JD, RAC - Chief Medical Officer: Marc G. Odrich, MD - Secretary: Mac Thompson, LLD For more information please visit www.tearsolutions.com
TearSolutions has raised $3.5M across 2 funding rounds on record, the most recent an undisclosed round of $520k announced in Nov 2025.
That round is below the $3.5M median round size for Consumer Goods companies tracked on FundedIQ over the last two years.
TearSolutions Company Profile and Key Stats
Latest funding round on record: Nov 2025.
TearSolutions Funding Rounds
TearSolutions raised $3.0M in a Series B announced in Nov 2024.
1 years later, an undisclosed round of $520k was announced in Nov 2025.
TearSolutions Founders and Leadership Team
Contact details for the TearSolutions team: 1 of 2 have an email address on file, 1 has a LinkedIn profile.
Start 14-day free trial →TearSolutions Funding Compared to Other Consumer Goods Startups
TearSolutions' latest round of $520k is below the median round in Consumer Goods. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like TearSolutions in Consumer Goods and Charlottesville
Companies Similar to TearSolutions
Glimmer Wish is a manufacturer of clean, dermatologist-tested self-care products designed for fun, safe…
PostCurious publishes narrative tabletop puzzle adventure games that combine story, puzzles, and tactile…
Steele Hair Gallery is a boutique salon that offers color, curly hair care, precision cuts, and styling for…
Solum is a sustainable materials company developing bio-based rubber additives replacing toxic petrochemical…
4amskin is a research-backed skincare brand that creates luxurious, all-in-one products designed to simplify…
Crown Affair is a brand that focuses on high-end hair-care products and merchandise. The company, established…
Phoam Labs creates environmentally-friendly foam for the floral industry that is renewable, non-toxic, and…
Baked Cravings is a manufacturing company that offers fresh-baked nut-free & peanut-free cupcakes.
The Pickled Chef produces pickled foods, fermented products, and condiments using natural ingredients and…
BuildForever build products that feel personal, magical and deeply human.
Renegade Game Studios is a company that operates in the gaming industry. The company designs and publishes a…
Kinderfarms is a company that produces health powders and beverages. Their main focus is on creating…
TearSolutions Funding FAQs
What does TearSolutions do?
TearSolutions Inc. is a Delaware Corporation based in Charlottesville, VA. The company has successfully completed a well-powered 204 patient Phase II Proof of Concept clinical trial for the treatment of ocular surface disease in primary Sjögren’s Syndrome patients. Statistically significant improvement in both sign and symptom at two weeks was found. The trial compared vehicle and two doses of LacripepTM, a novel 19 AA peptide that is present in normal tears and deficient in all forms of dry eye. The peptide restores homeostasis to the ocular surface, in particular the barrier function of the corneal epithelium and normal function of sensory nerves at the corneal surface in preclinical animal models. Restoration of epithelial barrier function can be measured clinically as a decrease in corneal fluorescein staining while the improvement in sensory nerve function restores normal production of the components of tears: the aqueous via reinnervation of lacrimal glands, the lipid via reinnervation of meibomium glands and the mucin via reinnervation of goblet cells. Improvement in fluorescein staining and tear production (Schirmer tear test) are clinical ‘signs’ of ocular suface disease that have been used in the FDA approval of Xiidra and Restasis, respectively. Lacripep was discovered at the University of Virginia with NIH National Eye Institute funding as a naturally occurring fragment of the larger 119 AA protein, lacritin, in an unbiased screen for novel factors capable of addressing dry eye. Management team - CEO/President: Anil Asrani - Executive Chair: Robert Dempsey - CSO/Cofounder: Gordon W. Laurie PhD, FARVO - CFO: Colin M. Rolph - Chief Regulatory Officer: Michelle Carpenter JD, RAC - Chief Medical Officer: Marc G. Odrich, MD - Secretary: Mac Thompson, LLD For more information please visit www.tearsolutions.com
How much funding has TearSolutions raised?
TearSolutions has raised $3.5M across 2 rounds on record. The most recent is an undisclosed round of $520k announced in Nov 2025.
When did TearSolutions last raise funding?
TearSolutions' most recent funding round on record is an undisclosed round of $520k, announced in Nov 2025.
Who founded TearSolutions?
FundedIQ lists Mark B Logan (Founder) at TearSolutions.
Where is TearSolutions headquartered?
TearSolutions is based in Charlottesville, Virginia, United States.
How many employees does TearSolutions have?
TearSolutions is in the 1-10 employee band.
How does TearSolutions' funding compare to other Consumer Goods startups?
TearSolutions' latest round of $520k is below the $3.5M median round size for Consumer Goods companies on FundedIQ across 465 tracked companies over the last two years.
About FundedIQ's TearSolutions Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for TearSolutions is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.